"HOPKINTON, Mass., Oct. 6 /PRNewswire/ -- Creative BioMolecules, Inc. (Nasdaq: CBMI - news) announced today that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for research into morphogenic protein-based therapies for the treatment of Parkinson's Disease. The research is being conducted in collaboration with Paula C. Bickford, Ph.D., Associate Professor of Pharmacology at the University of Colorado's School of Medicine. "Creative BioMolecules has proprietary rights to a family of neurotrophic proteins with demonstrated activity in multiple animal models of disease including stroke and initial results in Parkinson's Disease. This grant will support research to evaluate the potential of these proteins to restore dopaminergic neurons, the brain cells damaged in Parkinson's Disease, and promote the reestablishment of signaling pathways in the central nervous system. "Dr. Bickford commented, ``Factors that promote the survival or prevent the progressive deterioration of dopaminergic neurons may have significant benefit in treating Parkinson's Disease. Early research indicates that OP-1 may represent the first protein in an exciting family of neurotrophic factors. ..." "NOTE: Creative BioMolecules, Inc. makes available its latest news releases on the Internet at http://www.creativebio.com and http://www.prnewswire.com or by facsimile by calling Fax On Demand at 1-800-758-5804, extension 212213."